MKM Partners Cuts Target on Targacept (TRGT) to $6 After TC-5619 Fails in ADHD
Tweet Send to a FriendGet Alerts TRGT Hot Sheet
Price: $4.89 +1.66%
Rating Summary:
1 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Rating Summary:
1 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Trade TRGT Now!
MKM Partners lowered its price target on Buy-rated Targacept (NASDAQ: TRGT) from $11.50 to $6 after the company announced negative top-line results from a Phase 2 trial of TC-5619 as a treatment for inattentive-predominant ADHD. TC-5619 did not meet the primary outcome measure of change on the inattention subscale of the CAARS-INV, and Targacept will not pursue further development of TC-5619 in ADHD.
"We previously valued the TC-5619 program at $150mn, which included both ADHD and schizophrenia. As a result of the failed ADHD trial we are lowering our valuation of the TC-5619 program from $150mn to $25mn," the analyst comments. The schizophrenia trial is ongoing and should have results in mid-2013."
For an analyst ratings summary and ratings history on Targacept click here. For more ratings news on Targacept click here.
Shares of Targacept closed at $4.31 yesterday, with a 52 week range of $4.04-$19.54.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
"We previously valued the TC-5619 program at $150mn, which included both ADHD and schizophrenia. As a result of the failed ADHD trial we are lowering our valuation of the TC-5619 program from $150mn to $25mn," the analyst comments. The schizophrenia trial is ongoing and should have results in mid-2013."
For an analyst ratings summary and ratings history on Targacept click here. For more ratings news on Targacept click here.
Shares of Targacept closed at $4.31 yesterday, with a 52 week range of $4.04-$19.54.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- Invesco (IVZ) Organic Growth Continues to Impress - Jefferies
- Wedbush Starts Intuitive Surgical (ISRG) at Outperform
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
